The Food and Drug Administration has approved Celltrion’s Omlyclo (omalizumab-igec) as a biosimilar designated as interchangeable with Xolair (omalizumab) for the treatment of moderate to severe ...

(Reuters/Eloisa Lopez) MANILA — Former Philippine President Rodrigo Duterte was arrested and taken into custody on Tuesday in Manila on an International Criminal Court warrant for the “war on drugs” ...

MANILA, March 11 (Reuters) - Former Philippine President Rodrigo Duterte was arrested and taken into custody on Tuesday in Manila on an International Criminal Court warrant for the "war on drugs ...

If I make it to the presidential palace, I will do just what I did as mayor. You drug pushers, hold-up men and do-nothings, you better go out. Because I'd kill you," he said during that campaign.

The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent litigation ...

Biotechnology firm Biocon Ltd on Friday (March 7) said its subsidiary Biocon Biologics Ltd has announced positive results from its phase 3 clinical trial for Yesintek, a biosimilar to ustekinumab ...

Omlyclo is the first interchangeable biosimilar to omalizumab (Xolair; Genentech, Novartis). Omlyclo was approved to treat the same conditions as Xolair. The FDA approved Celltrion’s omalizumab ...

Celltrion's Omlyclo (omalizumab-igec) is the first omalizumab biosimilar to be approved for US patients, and it was approved with interchangeability, making it easier for patients to switch to the ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy.

The FDA has approved seven biosimilars for the drug, though patent litigation has blocked their launches until now. The four ustekinumab biosimilars now available in the United States are ...

Teva Pharmaceuticals and Alvotech last Friday launched Selarsdi, a biosimilar to Stelara. The Food and Drug Administration has allowed the use of Selarsdi as an "interchangeable" substitute only ...

The biosimilar approval was based on a comprehensive clinical data package, which included a double-blind, randomized, active-controlled phase 3 trial (ClinicalTrials.gov Identifier: NCT04757376 ...